Natural Killer Cell (CYNK-001) Infusions in Adults With AML
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Analgesics
- Alkylating Agents
- Peripheral Nervous System Agents
- Analgesics Non-narcotic
- Anti-infective Agents
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Neoplasms
- "Hematologic Diseases"
- Hematologic Neoplasms
- Leukemia Myeloid Acute
- Leukemia in Remission
- Immunologic Factors
- Leukemia, Myeloid
- Immunosuppressive Agents
- Neoplasms by Histologic Type
- Leukemia
- Physiological Effects of Drugs
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Experimental: Cyclophosphamide + Fludarabine + CYNK-001. On Days 0, 7, and 14, CYNK-001 at 3 varying dose levels.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04310592
- Collaborators
- Not Provided
- Investigators
- Study Director: Solveig Ericson, MD, PhD Celularity, Inc.
Get Well Soon